


CLAIMS

1. A compound having general formula I:



where

$Q^-$  represents the conjugate base of a pharmaceutically suitable organic or inorganic acid;

$R_1$  and  $R'_1$  represent, independently of each other, a radical selected from the group formed by H and  $C_{1-6}$  alkyl optionally substituted by trifluoromethyl, hydroxyl or alkoxy;


$R_2$  and  $R'_2$  represent, independently of each other, an aryl radical optionally substituted by halogen, trifluoromethyl, hydroxyl,  $C_{1-6}$  alkyl, amino or alkoxy;

$R_3$  and  $R'_3$  represent, independently of each other, either a radical selected from the group formed by H, halogen, trifluoromethyl, hydroxyl, amino, alkoxy and  $C_{1-6}$  alkyl optionally substituted by trifluoromethyl, hydroxyl, amino or alkoxy, or together with  $R_4$  and  $R'_4$  respectively, and independently of each other, a  $-CH=CH-CH=CH-$  radical optionally substituted by halogen, trifluoromethyl, hydroxyl,  $C_{1-6}$  alkyl, amino or alkoxy;

$R_4$  and  $R'_4$  represent, independently of each other, either a radical selected from the group formed by H and  $C_{1-6}$  alkyl optionally substituted by halogen, trifluoromethyl, hydroxyl, amino or alkoxy, or together with  $R_3$  and  $R'_3$  respectively, and independently of each other, a  $-CH=CH-CH=CH-$  radical optionally substituted by halogen, trifluoromethyl, hydroxyl,  $C_{1-6}$  alkyl, amino or alkoxy; and


A represents a spacer group.

2. A compound according to claim 1, characterized in that spacer A has a formula selected from:




II


wherein m, n and p represent integers which can have the following values: m = 0, 1; n = 0, 1-10; p = 0, 1; with the condition that m, n and p do not take the value of zero at the same time.




III



IV



V



















VI





3. A compound according to previous claims, characterized in that  $R_2$  and  $R'_2$  represent, independently of each other, a phenyl radical optionally substituted by halogen, trifluoromethyl, hydroxyl,  $C_{1-6}$  alkyl, amino and alkoxy.

4. A compound according to claim 3, characterized in that  $R_1$  and  $R'_1$  represent a methyl radical, and in that  $R_2$  and  $R'_2$  represent, independently of each other, a phenyl radical optionally substituted by one or more halogen substituents.

5. A compound according to the previous claims, characterized in that both  $R_3$  and  $R_4$  and  $R'_3$  and  $R'_4$  together represent, although independently of each other, a  $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$  radical optionally substituted by one or more halogen substituents.

6. A compound according to claim 1, characterized in that it has the following substituents:

No.	$R_3, R_4^*$	$\text{NR}_1\text{R}_2$	A	Code
1	H, H			ACG560B
2	H, H			ACG416B
3	H, H			ACG548B
4	H, H			ACG604A
5	$-(\text{CH}=\text{CH})_2-$			RSM964A
6	$-\text{C}^5\text{H}=\text{C}^6\text{H}-$ $\text{C}^7\text{Cl}=\text{C}^8\text{H}-$			RSM820C
7	$-(\text{CH}=\text{CH})_2-$			RSM932A
8	$-\text{C}^5\text{H}=\text{C}^6\text{H}-$ $\text{C}^7\text{Cl}=\text{C}^8\text{H}-$			RSM824B

9	$-(\text{CH}=\text{CH})_2-$			RSM936A
10	$-\text{C}^5\text{H}=\text{C}^6\text{H}-$ $\text{C}^7\text{Cl}=\text{C}^8\text{H}-$			RSM828B

\*R<sub>3</sub> and R<sub>4</sub> can mean either each one is hydrogen or both form a single radical.

7. A compound according to claim 6, characterized in that Q represents Br (bromide) or F<sub>6</sub>P (hexafluorophosphate).

8. A pharmaceutical formulation comprising at least one compound defined in claims 1 to 7 as an active ingredient.

9. A compound according to claims 1 to 7 for its use in medicine, particularly for its use in the treatment of cancer, for antiviral, antiparasitic and antifungal treatment.

10. A compound according to claims 1 to 7 for the treatment of breast, lung, colorectal and pancreatic cancer.

11. The use of a compound according to claims 1 to 7 in the manufacture of a medicament, particularly for the treatment of cancer, for antiviral, antiparasitic and antifungal treatment.


12. The use of a compound according to claims 1 to 7 in the manufacture of a medicament for the treatment of breast, lung, colorectal and pancreatic cancer.

13. A process for preparing a compound according to claim 1 comprising reacting:

- a) the corresponding heterocyclic derivative of formula VII and the dihalogenated derivative AX<sub>2</sub> (where X represents the halogen atom: Cl, Br or I) in 2:1 molar amounts in an organic solvent or,

- b) the corresponding heterocyclic derivative of formula VII and the dihalogenated derivative  $AX_2$  (where X represents the halogen atom: Cl, Br or I) in a 1:1 molar ratio in an organic solvent, in order to give a monoquaternized product which is again reacted with another different heterocyclic derivative molecule, in a 1:1 molar ratio, using an organic solvent that is more polar than the first one.

14. A compound having general formula VII:



VII


where

- $R_1$  represents a radical selected from the group formed by H and  $C_{1-6}$  alkyl optionally substituted by trifluoromethyl, hydroxyl or alkoxyl;
- $R_2$  represents an aryl radical optionally substituted by halogen, trifluoromethyl, hydroxyl,  $C_{1-6}$  alkyl, amino or alkoxyl
- $R_3$  represents either a radical selected from the group formed by H, halogen, trifluoromethyl, hydroxyl, amino, alkoxyl and  $C_{1-6}$  alkyl optionally substituted by trifluoromethyl, hydroxyl, amino or alkoxyl, or together with  $R_4$  a  $-CH=CH-CH=CH-$  radical optionally substituted by halogen, trifluoromethyl, hydroxyl,  $C_{1-6}$  alkyl, amino or alkoxyl;
- $R_4$  represents either a radical selected from the group formed by H, and  $C_{1-6}$  alkyl optionally substituted by halogen, trifluoromethyl, hydroxyl, amino or alkoxyl, or together with  $R_3$  a  $-CH=CH-CH=CH-$  radical optionally

substituted by halogen, trifluoromethyl, hydroxyl, C<sub>1-6</sub> alkyl, amino or alkoxyl.


15. Compounds according to claim 14 having formulas:

4-(4-chloro-*N*-methylanilino)quinoline



VIII A

and 7-chloro-4-(4-chloro-*N*-methylanilino)quinoline



VIII B.